Physician profile
Arif Bari
NPI 1932188695
$2,130.78
in general payments reported to CMS, 2019-2025
32 companies · $669 in 2025
The $669 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $340 · 2021: $142 · 2022: $199 · 2023: $344 · 2024: $149 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.74 |
| Education | $280.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $377.84 | 2019-2022 | |
| Daiichi Sankyo INC. | $248.77 | 2019-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $220.80 | 2019-2025 | |
| Abbvie INC. | $214.44 | 2022-2025 | Venclexta |
| Incyte Corporation | $149.99 | 2024-2025 | |
| Pfizer INC. | $122.18 | 2019-2025 | |
| Gilead Sciences, INC. | $114.98 | 2019-2025 | Trodelvy |
| Genentech USA, INC. | $101.73 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $73.85 | 2023-2025 | Enhertu, Imfinzi |
| Pharmacyclics LLC, An Abbvie Company | $53.88 | 2021-2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $46.90 | 2020-2023 | Keytruda, Lynparza |
| Emd Serono, INC. | $46.07 | 2023-2025 | Bavencio |
| Beone Medicines USA, INC. | $30.12 | 2025 | Tevimbra |
| Array Biopharma INC | $28.31 | 2020-2025 | Xalkori, Lorbrena, Braftovi |
| Exelixis INC. | $24.63 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $22.10 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $21.02 | 2025 | Libtayo |
| Stemline Therapeutics INC. | $20.45 | 2023 | Orserdu |
| Deciphera Pharmaceuticals INC. | $20.02 | 2025 | Qinlock |
| Janssen Biotech, INC. | $19.83 | 2025 | Talvey, Darzalex |
| Celgene Corporation | $18.84 | 2025 | Reblozyl |
| Pharmaessentia USA Corporation | $17.88 | 2023 | Besremi |
| Kite Pharma, INC. | $17.08 | 2023 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $16.33 | 2023 | Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $15.76 | 2023 | Iclusig |
| Sumitomo Pharma America, INC. | $14.77 | 2023 | Orgovyx |
| Rigel Pharmaceuticals, INC. | $14.19 | 2023 | Rezlidhia, Tavalisse |
| Seagen INC. | $14.15 | 2020 | |
| Genmab U.S., INC. | $14.15 | 2025 | Tivdak |
| Recordati_rare_diseases_inc. | $14.13 | 2024 | Enjaymo |
| Jazz Pharmaceuticals INC. | $11.96 | 2019 | |
| Clovis Oncology, INC. | $3.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arif Bari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.